molecule

Cannabidiol’s history stretches from ancient folk medicine to contemporary, tightly regulated clinical trials. Cannabis was used medicinally in many cultures for millennia — it appears in classical Chinese pharmacopoeia attributed to Emperor Shén Nóng around 2700–2800 BCE and is recorded across Asia, the Middle East and India for pain, spasms and other ailments. (The University of Sydney)

In the modern Western medical era, an important early figure was the Irish physician William B. O’Shaughnessy, who in the late 1830s (published 1839) documented cannabis preparations for treating pain, spasms and cholera while working in Calcutta and helped introduce cannabis into Victorian medicine. (The Public Domain Review)

The chemical study of cannabis compounds began in the 20th century. In 1940 Roger Adams and colleagues isolated cannabidiol (CBD) from hemp oil (they reported it as a derivative), marking the first clear chemical isolation of CBD from the plant. Early mid-century work identified cannabinoids but left some structural questions unresolved. (American Chemical Society)

A decisive advance came in the 1960s with the Israeli chemist Raphael Mechoulam and collaborators: in 1963 Mechoulam and Shvo published the correct structure of cannabidiol, and in 1964 Mechoulam (with Yechiel Gaoni) elucidated the structure of Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent. These structural discoveries opened the door to systematic pharmacology and later to the discovery of endogenous cannabinoids (the body’s own “endocannabinoid” system). (PubMed)

From the 1970s onward, basic science and animal studies expanded rapidly, and by the 1990s researchers had identified endocannabinoids and cannabinoid receptors, providing a physiological framework that explained how plant cannabinoids like CBD could influence pain, seizure thresholds, mood and inflammation. This era set the stage for clinical research into specific therapeutic uses. (PMC)

The 2000s–2010s saw the first regulatory approvals for cannabis-derived medicines: nabiximols (Sativex®, a roughly 1:1 THC:CBD oromucosal spray) gained approvals in several countries for spasticity in multiple sclerosis in and after 2010, reflecting acceptance of standardized botanical extracts in some national formularies. Then, in a landmark for CBD specifically, the U.S. Food and Drug Administration approved Epidiolex® (a purified, plant-derived CBD oral solution) on 25 June 2018 for certain severe childhood epilepsies (Lennox–Gastaut and Dravet syndromes, later expanded), based on randomized controlled trials showing seizure reduction. Those regulatory steps mark CBD’s movement from isolated compound and experimental therapy into licensed medical products. (Therapeutic Goods Administration (TGA))

Since those approvals, research has broadened: clinical trials and observational studies have investigated CBD for pain, anxiety, sleep, inflammation and a range of neurological and psychiatric conditions, producing mixed but sometimes promising results. At the same time, a massive consumer market for unregulated CBD products emerged, creating regulatory and quality-control challenges that health agencies continue to address. The scientific arc therefore runs from ancient empirical use, through mid-20th-century chemical isolation and 1960s structural elucidation, to modern mechanistic science and the first regulatory endorsements of CBD-based medicines in the 2010s. (PMC)

(Source : ChatGPT)

EGCG (pronounced "E-G-C-G") stands for epigallocatechin-3-gallate, a specific type of polyphenol found most abundantly in green tea. Chemically, it belongs to a group called catechins — plant-made molecules that often act like mild protective chemicals for the plant and, when we consume them, can interact with our bodies in interesting ways. If you drink green tea or matcha, EGCG is one of the main active ingredients you’re getting.

At a practical level, EGCG is known for two broad properties: it can act as an antioxidant and it can influence cellular signalling. As an antioxidant, EGCG can neutralize some reactive molecules that damage cells (often called free radicals). But more importantly, it also turns on the body’s own protective systems — for example, cellular pathways that boost the production of enzymes that clean up oxidative stress. Beyond that, EGCG can change how cells talk to each other by modifying signalling pathways that control inflammation, growth, and survival. In plain terms, it can damp down excessive inflammatory signals in some situations and can slow down abnormal cell growth in others.

A lot of the excitement around EGCG comes from laboratory and animal studies showing it affects processes linked to heart health, brain health, metabolism, and cancer. In cells and animals, EGCG has been shown to reduce inflammation, protect nerve cells, improve blood vessel function, and interfere with pathways that cancer cells use to grow. However, what happens in a test tube or a mouse does not always happen the same way in people. When humans drink green tea, EGCG is partially broken down in the gut and liver into other compounds, and the amounts that reach different tissues are smaller and more complex than the pure compound used in lab experiments. That’s why clinical evidence in people is more mixed and why researchers are careful about making strong health claims.

How you consume EGCG matters. Drinking green tea delivers EGCG together with water, caffeine, and other tea compounds, and this is generally considered safe for most people. Concentrated supplements deliver much higher doses of EGCG than a few cups of tea and have been linked, in rare cases, to liver problems. EGCG can also interfere with the absorption of non-heme iron (the kind found in plants) and can interact with certain medications. Because of this, supplements should be used cautiously and ideally under medical advice.

Another important point is that EGCG doesn’t act alone. The gut microbes in your intestines transform EGCG into other molecules, and those transformations can influence what effects occur in your body. So the final biological activity you get from green tea depends not only on the EGCG amount but also on how your body and your microbiome process it.

In short, EGCG is a biologically active compound in green tea with antioxidant and cell-signalling effects that may support aspects of health. Most evidence supports drinking green tea as a safe way to get modest amounts of EGCG; high-dose supplements are more uncertain and carry more risk. If you’re considering concentrated EGCG products for health reasons, it’s wise to talk with a healthcare professional first.

(Source : ChatGPT) (Image : FreePik)

Polyphenols are a large family of compounds found in plants — things like tea, berries, apples, onions, wine, and many herbs and spices. When people say polyphenols have “immunomodulatory” effects, they mean these compounds can change how the immune system behaves. Importantly, they don’t act like a single on/off switch. Instead they act more like a dimmer or a thermostat: in some situations they dial down excessive inflammation, and in other situations they can support immune defences that are too weak. Below I’ll explain, in plain language, the main ways scientists think polyphenols achieve those effects.

One of the simplest ways polyphenols influence immunity is through their effect on oxidative stress. Immune cells produce reactive oxygen species (ROS) as part of the attack on microbes, but too much ROS can damage tissues and keep inflammation going. Many polyphenols are antioxidants — they neutralize some ROS directly and also turn on the body’s own antioxidant defenses (for example by activating the Nrf2 pathway). By lowering oxidant damage, polyphenols help prevent an inflammatory cycle that would otherwise perpetuate tissue injury and overactive immune responses.

Another major route is by changing immune signalling inside cells. Immune responses are controlled by networks of proteins and chemical signals — transcription factors like NF-κB and signaling pathways such as MAP kinases. These pathways tell immune cells to release inflammatory molecules called cytokines (examples you may have heard: TNF-α, IL-6, IL-1β). Many polyphenols interfere with those intracellular signals so that the production of pro-inflammatory cytokines is reduced. At the same time, some polyphenols can enhance anti-inflammatory signals (for example increasing IL-10 or supporting regulatory T cells). The net result is a shift in the balance away from excessive inflammation toward a more controlled response.

Polyphenols also act on specific kinds of immune cells. They can affect macrophages (the “big eater” cells that clean up debris and secrete signals), dendritic cells (which present bits of invaders to T cells), and different types of T cells (which coordinate adaptive immunity). For instance, polyphenols can make macrophages less likely to adopt a highly inflammatory state, and they can influence whether T cells become the aggressive, inflammation-driving types (Th1 or Th17) or the regulatory types (Tregs) that calm things down. By nudging these cell decisions, polyphenols shape how strong and what kind of immune response develops.

The gut is another important place where polyphenols influence immunity. Many polyphenols aren’t absorbed unchanged — they are altered by the microbes in the gut into smaller molecules, and those metabolites can have biological activity. Polyphenols also change the composition and behavior of the gut microbiota itself. Because a large portion of the immune system sits in or near the gut (the gut-associated lymphoid tissue), changes in microbiota and in microbial metabolites translate into changes in systemic immune tone and local gut immunity. In short, polyphenols can act indirectly through microbiome shifts as well as directly on immune cells.

There are other mechanisms worth noting. Polyphenols can block or reduce activation of inflammasomes — protein complexes that trigger a particular type of inflammatory response — and they can interfere with pattern-recognition receptors such as Toll-like receptors (TLRs), which are the immune system’s early-warning detectors for invaders. Some polyphenols can also alter gene expression by epigenetic means (changing how tightly certain genes are turned on or off), which can produce longer-lasting effects on immune behavior.

It’s important to keep perspective about what this science means in the real world. Much of the detailed mechanistic work comes from cell culture or animal studies where concentrations of polyphenols and direct exposures are very different from what happens when you eat a blueberry or drink tea. In humans, polyphenols are extensively metabolized, and only small amounts of parent compounds reach the bloodstream; often the metabolites — or the changes caused in the microbiome — are the active players. Clinical evidence that eating polyphenol-rich foods reduces disease risk or meaningfully treats immune disorders exists in some cases, but it’s variable and context-dependent. Also, because polyphenols can both raise and lower different parts of the immune response, they are not universally “immune-boosting” in a simple sense — their effect depends on the existing state of the immune system.

To sum up: polyphenols modulate immunity through antioxidant effects, by altering intracellular signalling and cytokine production, by influencing immune cell types and their decisions, by shaping gut microbiota and their metabolites, and through other routes like inflammasome inhibition and epigenetic changes. They tend to promote balance — limiting unnecessary or damaging inflammation while preserving or supporting appropriate defensive responses — but the details depend on the specific polyphenol, its metabolites, dose, and the person’s biology. If you’re interested in practical takeaways, a diet with a variety of polyphenol-rich plant foods is a reasonable, low-risk way to support overall health, but it’s not a substitute for medical treatment when the immune system is actively malfunctioning.

(Source : ChatGPT)

There is suggestive evidence that oolong tea can help some inflammatory skin problems—most convincingly for atopic dermatitis (eczema)—but the data are limited, and for psoriasis the evidence is largely preclinical or anecdotal rather than proven in clinical trials.

Longer, medical-style explanation:

Oolong tea is derived from Camellia sinensis and contains a mix of tea polyphenols (catechins and their oxidation products), modest amounts of caffeine, and a range of other bioactive molecules. Those polyphenols have antioxidant, anti-inflammatory and “antiallergic” actions in laboratory studies: they can reduce proinflammatory cytokine signaling, stabilize or reduce mast-cell activation, and scavenge reactive oxygen species — mechanisms that are plausibly relevant to inflammatory skin diseases such as atopic dermatitis. Reviews of tea polyphenols and focused papers on the catechin EGCG summarize these pathways and the experimental evidence supporting them. (PMC)

Clinical human data for oolong and eczema are modest but noteworthy. A controlled clinical series conducted in Japan reported improvement in a substantial fraction of patients with treatment-resistant atopic dermatitis who drank oolong tea daily; roughly two-thirds showed marked or moderate improvement after one month and more than half maintained a response at six months in that observational/clinical series. The protocol, as used in published descriptions and integrative dermatology summaries, involved steeping a defined amount of dried oolong leaves and drinking the infusion divided through the day. These results are encouraging but must be read in context: the study was relatively small, not a large double-blind randomized controlled trial, and confounding (diet, concurrent treatments, placebo effects) cannot be fully excluded. (PubMed)

Laboratory and animal research strengthens biological plausibility. Recent preclinical work comparing tea extracts shows that oolong and other tea extracts can reduce scratching, epidermal hyperplasia, mast cell counts and key inflammatory mediators in mouse models of allergic dermatitis. Separate mechanistic studies find that both systemic and topical administration of tea catechins (especially EGCG) reduce acute and chronic itch and downregulate inflammatory signaling in keratinocytes and immune cells — findings that help explain the clinical signals seen in some human reports. (MDPI)

When it comes to psoriasis the picture is different. Psoriasis is a Th17-driven, hyperproliferative disorder of epidermis and immune signaling; laboratory and animal studies show that EGCG and other polyphenols can attenuate psoriasiform inflammation in mouse models and modulate pathways (STAT3, NF-κB, IL-17 axis) relevant to psoriasis. However, high-quality clinical trial evidence of benefit for oral oolong tea in people with psoriasis is essentially lacking, and available human reports tend to be anecdotal or extrapolated from green tea/EGCG work or small topical formulation studies. Thus, while the molecular data and animal models support the possibility that tea polyphenols could help, clinical proof for oolong in psoriasis is currently insufficient. (SpringerLink)

Practical clinical considerations and safety: if patients wish to try oolong as an adjunctive, a few practical points are important. Moderate consumption (a few cups daily) is generally well tolerated for most adults, but oolong contains caffeine and can interfere with sleep or exacerbate anxiety in sensitive individuals; tea also reduces non-heme iron absorption if taken with iron-rich meals and can contribute fluoride exposure if consumed in very large amounts. Patients with significant or progressive dermatitis or psoriasis should not stop standard prescribed therapies in favour of tea alone; instead oolong can be considered as a complementary measure and patients should discuss it with their dermatologist. Finally, topical preparations containing stabilized tea catechins are an active area of research and may offer different risk/benefit profiles compared with simply drinking tea. (PMC)

Bottom line: the best clinical signal for oolong tea is in atopic dermatitis, where limited human data plus supportive preclinical studies indicate a possible benefit; for psoriasis the evidence is mainly preclinical and anecdotal at present. The biological plausibility is strong because tea polyphenols are anti-inflammatory and immunomodulatory, but higher-quality randomized clinical trials and standardized dosing studies are still needed before oolong can be recommended as a proven treatment. (PubMed)

(...) Green tea has stronger and more consistent evidence (especially due to EGCG) for anti-inflammatory and topical benefits in skin conditions; oolong shows promise—notably for atopic dermatitis—but the clinical data are smaller and less robust.

(Source : ChatGPT) (Image : Qwen)

Polyphenols are a large, naturally occurring family of compounds found in plants — think the pigments, tannins and bitters that give fruits, vegetables, tea, coffee, chocolate and wine their color and flavor. Chemically diverse (groups include flavonoids like flavanols and anthocyanins, phenolic acids, stilbenes such as resveratrol, and lignans), polyphenols are not a single nutrient but a broad class of molecules that interact with our bodies in many ways. Their health effects come from a mix of direct biochemical activity and indirect influences mediated by digestion, metabolism and the gut microbiome.

One of the most widely discussed actions of polyphenols is antioxidant activity. In laboratory conditions they can neutralize reactive oxygen species and reduce oxidative damage to cells and biomolecules. In the human body the effect is more complex: many polyphenols are metabolized quickly and their circulating concentrations are low, so much of the beneficial activity appears to come from signaling effects — they influence cellular pathways that control inflammation, stress responses, and gene expression — rather than simply “mopping up” free radicals. Through these signaling roles, polyphenols can help reduce chronic, low-grade inflammation that contributes to cardiovascular disease, some metabolic disorders and age-related tissue damage.

Cardiovascular benefits are among the most consistently observed: polyphenol-rich diets (for example Mediterranean-style diets high in olive oil, nuts, fruits and vegetables) are associated with lower risks of heart disease. Mechanisms proposed include improved endothelial function (better blood-vessel dilation), reduced oxidation of LDL cholesterol, modest improvements in blood pressure and favorable effects on platelet function and blood lipids. Similarly, observational studies link higher polyphenol intake with lower risks of type 2 diabetes and metabolic syndrome, possibly through improved insulin sensitivity and reduced inflammatory signaling, though controlled trial results can be mixed depending on the compound, dose and population studied.

Polyphenols also interact strongly with the gut microbiota. Many polyphenols are poorly absorbed in the small intestine and reach the colon, where bacteria break them down into smaller metabolites. Those microbial metabolites often have biological activities of their own, and the interaction is two-way: polyphenols can alter the composition and function of the gut microbiome, potentially promoting beneficial bacterial strains. This gut-mediated pathway is increasingly recognized as an important route through which polyphenols influence metabolic health, immune function and even brain-related processes.

There is growing — though still evolving — evidence for neuroprotective effects. Certain polyphenols can modulate signaling pathways linked to neuronal survival, reduce neuroinflammation and improve cognitive function in animal models and some human trials. Epidemiological data suggest diets rich in polyphenol-containing foods correlate with slower cognitive decline, but causality and the optimal types or amounts remain under investigation.

Important caveats apply. Bioavailability varies widely between compounds: some are rapidly absorbed and modified; others are poorly absorbed and rely on microbial conversion. Food matrix and food preparation (raw vs cooked, whole fruit vs juice, presence of fat) influence absorption and effect. Because of this complexity, whole foods are generally preferred to isolated, high-dose supplements. Very high supplemental doses can cause adverse effects in some cases and may interfere with the absorption of non-heme iron; polyphenols can also influence drug-metabolizing enzymes and thus interact with medicines in certain situations. Finally, while many studies are promising, evidence strength varies by outcome — observational associations are common, but randomized controlled trials sometimes show smaller or inconsistent benefits.

In practice, the safest and most evidence-aligned approach is to obtain polyphenols through a varied plant-forward diet: colorful fruits and vegetables, berries, tea and coffee in moderation, cocoa or dark chocolate, nuts, whole grains, legumes, and extra-virgin olive oil provide a broad spectrum of polyphenols within a healthy dietary pattern. They’re not a magic bullet, but as part of an overall balanced diet and healthy lifestyle they contribute to reducing chronic inflammation, supporting vascular and metabolic health, nourishing the gut microbiome and potentially protecting brain health over the long term.

(Source : ChatGPT)

Cancer thrives by hijacking the body’s own basic survival systems, making it hard to attack tumors without collateral damage and side effects. Now, researchers at Cornell’s Weill Institute for Cell and Molecular Biology have discovered what may be a less invasive strategy that shows promise as a potential therapeutic pathway. 

New research has uncovered molecules that can preserve crucial cellular processes while blocking malignant proteins from their preferred attachment points on the healthy cell. The findings indicate a new approach to fighting cancer, one that triggers apoptosis – the self-destruct process – in melanoma and bone cancer cells.

The study, published Oct. 6 in the Journal of Medicinal Chemistry, was led by graduate student Nathan Frederick in collaboration with Jeremy Baskin, associate professor and Nancy and Peter Meinig Family Investigator in the Life Sciences in the Department of Chemistry and Chemical Biology in the College of Arts and Sciences, and the Weill Institute for Cell and Molecular Biology. It describes the discovery of the first compounds that directly target a family of proteins called PLEKHA, which help cancer cells grow and spread by interpreting lipid “messages” on cell membranes.

Inside every cell, phosphatidylinositol phosphate (PIP) lipids act like address labels, guiding proteins to the right locations and telling them when to act. Many cancers hijack these signals to keep dividing. Existing drugs that block the enzymes making PIPs can slow tumors but also disrupt vital processes that keep healthy cells functioning – particularly those controlling metabolism, immunity, and the ability for tissues to maintain a stable internal environment. These disruptions then lead to serious side effects, Frederick said.

The team in the Baskin lab flipped the problem around. Rather than turning off PIP production, they aimed to jam the signal receivers – the pleckstrin homology (PH) domains that allow PLEKHA proteins to grab onto lipid molecules. “We wanted to stop the lipid message from being read instead of silencing the entire system,” Frederick said.

Using computer modeling, the researchers screened more than 90,000 drug-like compounds to find those that could fit into the PH domain of PLEKHA4, a protein linked to melanoma growth. They discovered one molecule, called NF1, that bound tightly to the lipid pocket and competed with PIPs for space.

The team then created and tested chemical variations to fine-tune how well the compounds bound PLEKHA both in isolation and within cells. One version, NF14, worked especially well. They found it starts as an inactive “prodrug” that easily enters cells, and then once inside cells it’s converted into NF1 by natural enzymes, activating its cancer-killing potential.

When tested on melanoma and bone cancer cell lines, NF14 disrupted PLEKHA proteins’ grip on the cell membrane, triggering a chain reaction whereby the cells stopped dividing and triggered their own death through apoptotic pathways. Importantly, it showed little effect on cancer cells that make few PLEKHA proteins, suggesting it was hitting its intended target.
 

(Source : CornellChronicle)

The article "Insights from Traditional Chinese Medicine for Restoring Skin Barrier Functions" explains that your skin isn’t just a cover — it’s an active, smart barrier whose job is to hold in moisture and keep out things that can harm you, like germs, irritants and allergens. When that barrier is damaged, the skin becomes dry, itchy and inflamed, and people are more likely to get flare-ups of conditions such as eczema or psoriasis and even infections. The review looks at a wide range of substances used in Traditional Chinese Medicine (TCM) — plant and fungal extracts, and the chemical components inside them — and shows how many of these substances appear to help the skin rebuild and protect that barrier.

Instead of acting in one single way, these TCM-derived ingredients seem to help on several fronts at once. Some calm down inflammation so the skin stops reacting wildly and feeling hot or itchy. Others act like antioxidants, neutralizing damaging molecules that break down cells and slow healing. A number of compounds encourage skin cells to grow, mature and stick together in the right way so the outer layer becomes stronger. There are also ingredients that help the skin restore the natural fats (like ceramides) that lock moisture in, and a few that change the mix of microbes on the skin toward a healthier balance. The combination of these effects — less inflammation, less cell damage, improved cell renewal, and better lipid content — is exactly what the skin needs to mend its barrier and stay hydrated and comfortable.

The paper gives concrete examples: chemicals found in ginseng (ginsenosides), many plant flavonoids, certain alkaloids and long sugar molecules called polysaccharides all show useful actions in laboratory and animal studies. A handful of human studies are mentioned too — for example, small trials where red ginseng extract improved symptoms in people with atopic dermatitis, and studies where oxymatrine (an alkaloid) showed benefit in psoriasis. Those human results are encouraging but limited: the trials tend to be small, use different preparations and doses, and are not yet consistent enough to be taken as definitive proof that a given herb will help everyone.

One practical point the review raises is that how an ingredient is delivered matters a lot. Some of these natural molecules don’t penetrate the skin well or are unstable, so modern formulations (creams designed to get the active stuff into the right layer, or tiny carrier systems) can make a big difference in whether they actually work. The authors also stress caution: “natural” does not automatically mean safe for every person. Herbal products vary in strength and purity, can trigger allergic reactions in some people, and different studies use different preparations, which makes it hard to compare results across trials.

Overall, the message is hopeful but measured. A large body of laboratory work and animal studies shows clear ways that TCM ingredients can support barrier repair, and a few human studies suggest real benefit in people with inflammatory skin problems. However, the human evidence is still patchy and more large, well-designed clinical trials are needed to know which ingredients help which conditions, at what dose, and in what form. For someone with everyday dryness or mild inflammation, products containing some of these extracts might help as part of a skincare routine. For people with moderate to severe eczema or psoriasis, these herbal options are best considered complementary to proven medical treatments and discussed with a dermatologist before switching or stopping prescribed therapies.

(Source : ChatGPT)

Description

Turmeric (Curcuma longa) has been used as a medicinal substance in South Asia for millennia, first appearing in Indian medical traditions such as Ayurveda and later in other East Asian pharmacopeias; ancient texts and archaeological evidence place its therapeutic use for wounds, digestive and liver complaints, respiratory problems, and skin diseases as far back as three to four thousand years. (CNIB)

The active yellow pigment now called curcumin was first recognized by modern chemistry in the early 19th century: in 1815 chemists (notably Vogel and Pelletier) described a “yellow coloring-matter” from turmeric, and through the 19th and early 20th centuries workers purified the compound, determined its chemical structure (reported around 1910 as diferuloylmethane) and achieved laboratory synthesis by the 1910s. (PMC)

Despite this early chemical work, curcumin’s therapeutic potential attracted relatively little clinical attention until the latter half of the 20th century. Beginning in the 1970s and accelerating in the 1990s, scientists began laboratory and animal studies showing antioxidant, anti-inflammatory, and anticancer activities, which prompted a large increase in preclinical research and, later, human clinical trials. That surge of interest exposed both promise and practical limits: curcumin shows multiple biological effects in vitro, but its poor oral bioavailability and rapid metabolism in humans have been persistent obstacles to translating those findings into reliable medicines. (PMC)

Through the 2000s and 2010s investigators explored formulations (for example with piperine, liposomes, nanoparticles, or phospholipid complexes) to improve absorption and carried out an expanding series of clinical studies testing curcumin for conditions from osteoarthritis and inflammatory bowel disease to cancer prevention and adjunctive cancer therapy. While some trials reported encouraging signals, the evidence base remains uneven because of small study sizes, variable formulations, and mixed clinical endpoints; today curcumin occupies a space between traditional remedy and a subject of active pharmaceutical research rather than a routine, proven therapeutic. (bpspubs.onlinelibrary.wiley.com, PMC)

Mechanisms of action:

  Curcumin is a polyphenolic compound from turmeric that appears to help health mainly by dialing down inflammation and oxidative stress and by subtly reprogramming several cell-signaling networks. At the molecular level it interferes with pro-inflammatory pathways — most notably by inhibiting the IKK/NF-κB axis, which lowers production of cytokines (like TNF-α and IL-1β) and enzymes such as COX-2 that drive chronic inflammation. (PMC)

In parallel, curcumin boosts antioxidant defenses both by directly scavenging reactive oxygen species in biochemical assays and, more importantly in cells, by activating the Keap1–Nrf2 pathway so cells raise their own antioxidant and cytoprotective enzymes. This two-pronged action (less pro-inflammatory signalling plus more endogenous antioxidant activity) helps explain many of the compound’s reported benefits in models of arthritis, neuroinflammation, metabolic disease and tissue injury. (Nature, PMC)

Beyond those core effects, curcumin is a “multi-target” molecule: it modulates MAPK, PI3K/Akt, STAT3 and other signalling cascades, influences apoptosis and autophagy, and can alter gene expression and protein activity in ways that have attracted attention for cancer and metabolic disease research. Because it touches many pathways rather than a single receptor, its actions tend to be broad and context-dependent rather than narrowly specific. (PubMed, Taylor & Francis Online)

A practical limitation, however, is that native curcumin is poorly absorbed, rapidly metabolized and quickly eliminated in humans, so the impressive effects seen in cells or animals do not always translate to clinical benefit unless formulations or enhancers (for example piperine from black pepper, liposomes, nanoparticles or phospholipid complexes) are used to increase its systemic exposure. That pharmacokinetic reality is why most work on curcumin now pairs mechanistic understanding with formulation strategies to make the biology therapeutically useful. (PMC, mdpi.com)

Quotes :

“Wherever inflammation is a problem, curcumin may be helpful.” — Dr. Bharat B. Aggarwal (MD Anderson). 

“Curcumin seems to reduce these plaques.” — Dr. Gregory M. Cole (UCLA), on curcumin’s effects in Alzheimer’s models. 

“An even more blatant example is the use of turmeric for healing wounds, which is something every mother and grandmother does in every home in India.” — Vandana Shiva. 

The earliest surviving medical quotation that clearly names turmeric (Sanskrit haridrā) comes from the classical Ayurvedic compendia — notably the Charaka Saṃhitā (composed in its core over the first millennium BCE — commonly dated roughly between about 400 BCE and 200 CE). One commonly cited translated line from the therapeutic (cikitsā) passages reads, in English: “Haridra powder mixed with honey should be taken with the juice of Amalaki.” This is an explicit medicinal prescription found in the Charaka Saṃhitā (Chikitsā-sthāna) and is reproduced in modern English editions/translations of the text. 

It’s worth noting that botanical uses of turmeric may appear even earlier in non-Indian sources (some secondary accounts suggest mentions in Egyptian lists such as the Ebers Papyrus, c. ~1500 BCE), but those identifications are less direct or certain than the detailed therapeutic prescriptions preserved in the Ayurvedic samhitās.

(Source : ChatGPT)

Briefly: hydroxychloroquine can disturb the heart’s electrical repolarization by blocking certain ion channels, and that disturbance can lengthen the QT interval and create conditions that trigger dangerous ventricular arrhythmias; with long-term/high-dose use it can also cause a toxic cardiomyopathy and conduction blocks. 

A bit more of the science in plain language: heart muscle cells generate an action potential whose final phase of rapid repolarization (phase 3) depends largely on a potassium current called IKr, carried by channels encoded by the hERG (KCNH2) gene. Hydroxychloroquine interferes with those hERG/IKr channels, slowing repolarization and therefore prolonging the QT interval on the surface ECG. When repolarization is prolonged, the cell membrane can develop “early afterdepolarizations” that can trigger a specific dangerous arrhythmia called torsades de pointes, which can degenerate to ventricular fibrillation and sudden death. 

At higher or toxic concentrations hydroxychloroquine can also affect other cardiac ion channels (for example, sodium channels), which can widen the QRS complex and cause additional conduction disturbances — this is why very large doses or overdose produce more severe electrical instability, not just QT prolongation.

Separate from these electrical effects, chronic hydroxychloroquine exposure (usually after months–years of use, or with high cumulative dose) can damage cardiac muscle cells by interfering with lysosomal function and causing abnormal accumulation of metabolic material in myocytes. That toxic process can produce a cardiomyopathy (heart muscle dysfunction) and progressive conduction system disease (heart block, bradyarrhythmias). 

Risk of arrhythmia is amplified when other factors that delay repolarization are present: low potassium or magnesium, existing heart disease, older age, genetic long-QT predisposition, kidney or liver dysfunction (which increases drug levels), or co-administration of other QT-prolonging drugs such as azithromycin. For these reasons clinicians commonly check a baseline ECG, correct electrolytes, avoid combinations of QT-prolonging agents, and monitor the QT interval while someone is taking hydroxychloroquine. 

If you’re concerned about hydroxychloroquine and heart risk for yourself or someone else, the safest step is to discuss it with a clinician who can review the ECG, other medicines, and individual risk factors.

(...)  Use the lowest effective dose and avoid high “loading” regimens: for chronic indications clinicians typically use 200–400 mg daily (and generally avoid sustained doses above about 5 mg/kg actual body weight), because higher dosing raises the chance of cardiac toxicity. 

Before starting therapy check a baseline ECG and do not start (or pause) hydroxychloroquine if the corrected QT interval (QTc) is markedly prolonged (commonly used cutoff: QTc ≥ 500 ms) or if the patient has a history of congenital long-QT syndrome; if treatment is started in patients with intermediate risk, obtain a follow-up ECG within the first 48–72 hours and again as clinically indicated. (

Correct and normalize potassium and magnesium before and during treatment, avoid giving hydroxychloroquine together with other known QT-prolonging drugs (for example macrolide antibiotics such as azithromycin) when possible, and review other risk factors (older age, significant structural heart disease, severe renal or hepatic impairment) so you can lower the dose or choose an alternative if needed. 

If the QTc increases substantially (many protocols use an increase of ≈60 ms from baseline or an absolute QTc >500 ms as thresholds for dose reduction or stopping the drug) stop the drug and seek cardiology input. These precautions — conservative dosing, baseline and interval ECGs, electrolyte correction, and avoiding interacting drugs — are the standard posology/monitoring measures used to minimize arrhythmic risk. 

If you’re asking about a specific patient, share their current dose, recent ECG/QTc, and other medicines (no personal identifiers) and I can summarize how these rules would apply.

(Source : ChatGPT) (Image : Gemini)